The models examined the probability of being protected against malaria by either CS antibodies alone (model 1) or the combination of CS antibodies, CD4 T-cells expressing ≥ 2 cytokine/activation markers, and IFN-γ ELISpot (model 2) (see S1 Text for details). This evidence concerns the gene CD4 and malaria.